Infection or impaired wound healing in the immediate postoperative period leads to poor surgical outcomes and increased health care costs. Hyperglycemia has been shown to be a significant factor associated with postoperative infection ([@B1]--[@B3]). Chronic complications of diabetes such as neuropathy and nephropathy have been attributed to poor long-term control of blood glucose ([@B4]). Prolonged exposure to high glucose levels causes glycosylation of proteins, which impairs the activity of neutrophils and fibroblasts, leading to poor wound healing and infection ([@B5]).

A1C is formed by irreversible glycation of the amino acids in the hemoglobin molecule and reflects glycemic control over the previous 8--12 weeks. It is used as one of the diagnostic criteria for diabetes, and the American Diabetes Association recommends an A1C level \<7% as an acceptable glycemic target for most people ([@B6]). During the past decade, there have been suggestions that better long-term glycemic control may play a significant part in abating postoperative complications ([@B7]--[@B10]). However, the evidence is not conclusive ([@B11]).

The purpose of this prospective, observational pilot study was to determine whether elevated A1C is associated with a higher incidence of surgical wound problems, surgical site infection, or infection elsewhere within the first postoperative week. The secondary objective was to compare glycemic control and blood glucose variability during the immediate postoperative period.

Research Design and Methods {#s1}
===========================

All adult patients with diabetes who were scheduled for elective surgery were eligible to be enrolled into this institutional review board--approved, prospective, observational study. The subjects were identified from the daily operating-room schedule. Patients having cardiac surgery or a surgical procedure expected to take \<1 hour were excluded, as were those with preexisting infection and those taking antibiotics, steroids, chemotherapy, or immunosuppressive medications. The plan for this pilot study was to enroll all eligible, consecutive patients throughout a 6-month period until at least 25 subjects (a convenience sample) were enrolled in each of two groups: Group A, having an A1C \<7% and Group B, having an A1C ≥7%. A1C was assessed for all of the patients within 2 weeks of their surgery.

The data collected for each patient included demographic details (age, sex, weight, height, and comorbidities); diabetes details (type of diabetes, antidiabetic medications, and A1C); type and duration of surgery; all blood glucose values measured during the perioperative period; and the average of all blood glucose values measured during the first postoperative 24-hour period. Additional data collected focused on complications during the first postoperative 7 days, including surgical site infection or infection elsewhere (pyrexia or inflammation of the surgical site that resulted in administration of prophylactic antibiotic was recorded as postoperative infection); surgical wound problems (any inflammation, excessive oozing, delayed healing, or dehiscence of the surgical incision was recorded as a surgical wound problem); and other morbidity or mortality.

Statistical Methods {#s2}
-------------------

All continuous variables were analyzed by Mann--Whitney U test, and discrete variables were analyzed by Fisher's exact test. Descriptive statistics are reported as mean ± SD. Statistical analysis was conducted using R Project for Statistical Computing (The R Foundation, Vienna, Austria). *P* values \<0.05 were considered significant.

Results {#s3}
=======

During the study period, all consecutive patients with diabetes who were scheduled for elective, noncardiac surgery were selected. After excluding 13 subjects based on the exclusion criteria (6 for surgical duration \<1 hour, 2 for systemic steroid use, 4 for taking antibiotics, and 1 for preexisting infection), 25 subjects were enrolled into each study group (Group A for those with an A1C \<7% and Group B for those with an A1C ≥7%).

Patient Demographics {#s4}
--------------------

The two groups were comparable with respect to age, BMI, sex, associated comorbidities, and duration and type of surgical procedures ([Table 1](#T1){ref-type="table"}). Group B had significantly higher pre-induction glucose levels (*P* \<0.0001), higher A1C levels (*P* \<0.0001), and more patients on insulin (*P* = 0.02), whereas more patients in Group A were on metformin (*P* = 0.039).

###### 

Patient Demographics

                                                                    Group A (A1C \<7%) (*n* = 25)   Group B (A1C ≥7%) (*n* = 25)   *P*[†](#tblfn2){ref-type="table-fn"}
  ----------------------------------------------------------------- ------------------------------- ------------------------------ --------------------------------------
  Age (years)[\*](#tblfn1){ref-type="table-fn"}                     62.4 ± 10.1                     63.9 ± 11.8                    0.76
  Sex (male/female)                                                 14/11                           17/8                           0.56
  BMI (kg/m^2^)[\*](#tblfn1){ref-type="table-fn"}                   36.5 ± 10.1                     36.2 ± 5.9                     0.61
  Duration of surgery (hours)[\*](#tblfn1){ref-type="table-fn"}     2.9 ± 2.1                       3.5 ± 2.6                      0.40
  A1C (%)[\*](#tblfn1){ref-type="table-fn"}                         6.2 ± 0.4                       8.4 ± 1.1                      **\<0.0001**
  Pre-induction glucose (mg/dL)[\*](#tblfn1){ref-type="table-fn"}   123.5 ± 31.2                    189.8 ± 60.6                   **\<0.0001**
  Comorbidities (*n*)                                                                                                              
   Hypertension                                                     18                              22                             0.29
   Coronary artery disease                                          10                              7                              0.55
   Obstructive sleep apnea                                          14                              17                             0.56
   Malignancy                                                       5                               6                              1.00
   Chronic kidney disease                                           1                               6                              0.10
  Medications (*n*)                                                                                                                
   Insulin                                                          5                               14                             **0.020**
   Metformin                                                        20                              12                             **0.039**
   Other antidiabetic drugs                                         11                              12                             1.00
   Antihypertensive drugs                                           20                              22                             0.70
   Chronic pain medications                                         6                               13                             0.08
   Anticoagulants                                                   7                               3                              0.29
  Surgical procedure (*n*)                                                                                                         
   Gynecological                                                    1                               3                              0.60
   Orthopedic                                                       9                               6                              0.54
   Colorectal                                                       7                               5                              0.74
   Spinal                                                           4                               6                              0.72
   Urological                                                       2                               2                              1.00
   Head and neck                                                    1                               3                              0.60
   Vascular                                                         1                               0                              1.00

Mean ± SD.

Bold indicates statistical significance.

Glucose Levels and Postoperative Complications {#s5}
----------------------------------------------

One patient from Group A and 10 from Group B had pre-induction glucose values \>200 mg/dL, and 4 of these patients, all from Group B, developed postoperative infections. For each patient, all glucose values measured during the first 24 hours after surgery were averaged, and glucose variability was calculated. Average glucose during the first 24 hours was higher in Group B (*P* = 0.0016), as was glucose variability (*P* = 0.02) ([Table 2](#T2){ref-type="table"}). During the first postoperative day, of the 18 patients (5 from Group A and 13 from Group B) who had glucose values \>200 mg/dL ([Table 2](#T2){ref-type="table"}), 4 from Group B developed infections.

###### 

Postoperative Glucose and Infection Details

                                                                                                                Group A (A1C \<7%) (*n* = 25)   Group B (A1C ≥7%) (*n* = 25)   *P*[†](#tblfn4){ref-type="table-fn"}
  ------------------------------------------------------------------------------------------------------------- ------------------------------- ------------------------------ --------------------------------------
  Glucose on postoperative day 1 (mg/dL)[\*](#tblfn3){ref-type="table-fn"}                                      152.7 ± 32.4                    183.0 ± 40.4                   **0.0016**
  Glucose variability on postoperative day 1 (mg/dL)[\*](#tblfn3){ref-type="table-fn"}                          22.8 ± 12.3                     43.0 ± 32.2                    **0.02**
  Mean glucose \>200 mg/dL on postoperative day 1 (*n*)                                                         5                               13                             **\<0.05**
  Infection (at surgical site or elsewhere) or surgical wound problems (drainage, hematoma, dehiscence) (*n*)   1                               10                             **0.0046**
  Other complications (*n*)                                                                                                                                                    
   Acute renal failure                                                                                          0                               1                              ---
   Postoperative ileus                                                                                          1                               0                              ---
   Systemic lupus erythematosus flare-up                                                                        1                               0                              ---
   Supraventricular tachycardia                                                                                 0                               1                              ---

Mean ± SD.

Bold indicates statistical significance.

During the first postoperative week, nine patients developed surgical site infections or surgical wound problems, one developed a urinary tract infection, and one had hospital-acquired pneumonia. Of these 11 patients, 10 were in Group B, and 1 was in Group A ([Table 2](#T2){ref-type="table"}). This translates to a relative risk of 10.0 for a person with an A1C ≥7% to develop postoperative complications. The one patient from Group A who developed surgical wound hematoma had an A1C of 6.9%. There were no significant differences in the distribution of surgical procedures or the type of diabetes between those who did and did not develop postoperative wound problems. Apart from these 11 patients, 4 developed other complications ([Table 2](#T2){ref-type="table"}), all of which were self-limiting.

A subgroup analysis of those who developed postoperative complications showed that they had significantly higher A1C levels (*P* = 0.0021) and pre-induction glucose levels (*P* = 0.01), as well as a longer duration of intubation and lengthier intensive care unit stay ([Table 3](#T3){ref-type="table"}). Although glucose levels on the first postoperative day were comparable between groups, variability in glucose levels was significantly greater among those who developed complications (*P* = 0.04). Because reliable information about patients' duration of diabetes was not available, use of insulin was taken as a surrogate marker for severity of diabetes. Of the 14 patients in Group B who were on insulin, only 6 developed complications, whereas 4 of the 11 patients who were not on insulin developed complications. This was not a significant difference (*P* = 0.74).

###### 

Comparison of Patients Stratified by Development of Postoperative Complications

                                                                                 Developed Complications (*n* = 11)   Had No Complications (*n* = 39)   *P*[†](#tblfn6){ref-type="table-fn"}
  ------------------------------------------------------------------------------ ------------------------------------ --------------------------------- --------------------------------------
  Age (years)[\*](#tblfn5){ref-type="table-fn"}                                  66.6 ± 15                            62.2 ± 9.5                        0.21
  BMI (kg/m^2^)[\*](#tblfn5){ref-type="table-fn"}                                34.9 ± 6.5                           36.8 ± 8.6                        0.70
  Duration of surgery (hours)[\*](#tblfn5){ref-type="table-fn"}                  4.7 ± 3.2                            2.8 ± 1.9                         0.1
  Duration of intubation (hours)[\*](#tblfn5){ref-type="table-fn"}               14.5 ± 22                            3.7 ± 2.0                         **0.04**
  Length of intensive care unit stay (days)[\*](#tblfn5){ref-type="table-fn"}    1.0 ± 1.5                            0.1 ± 0.4                         **0.0023**
  A1C (%)[\*](#tblfn5){ref-type="table-fn"}                                      8.5 ± 1.5                            7.0 ± 1.2                         **0.0021**
  Median A1C (%)                                                                 7.9                                  6.5                               
  Pre-induction glucose (mg/dL)[\*](#tblfn5){ref-type="table-fn"}                194.9 ± 65.6                         145.9 ± 52                        **0.01**
  Glucose on postoperative day 1[\*](#tblfn5){ref-type="table-fn"}               159.9 ± 48.5                         168.8 ± 50.3                      0.59
  Glucose variability on postoperative day 1[\*](#tblfn5){ref-type="table-fn"}   43.0 ± 41.3                          19.6 ± 19.0                       **0.04**

Mean ± SD.

Bold indicates statistical significance.

Discussion {#s6}
==========

In this observational study, patients with diabetes who had an A1C ≥7% had a higher incidence of postoperative infection and surgical wound problems than those with an A1C \<7%. These patients also showed higher blood glucose levels with wider variability in the postoperative period.

Hyperglycemia leads to glycation of intracellular and extracellular proteins, which subsequently form advanced glycation end-products (AGEs), and this process has an important role in the pathophysiology of the chronic complications of diabetes such as nephropathy, neuropathy, and retinopathy. AGEs cause release of proinflammatory molecules such as tumor necrosis factor-α that can limit wound closure ([@B12]). In diabetic mice, AGEs have also been shown to affect the functioning of fibroblasts, leading to reduced collagen deposition, reduced proliferation of endothelial cells, and impaired angiogenesis ([@B13]).

Although it is widely accepted that hyperglycemia in the perioperative period is associated with surgical site infections and other complications after surgery ([@B1],[@B2],[@B10]), tight glycemic control in the postoperative period may act as a double-edged sword, increasing the risk of hypoglycemia and its associated higher mortality ([@B14]). Thiessen et al. ([@B15]) have suggested that, in patients undergoing cardiopulmonary bypass, accepting glucose values up to 180 mg/dL would be prudent to avoid hypoglycemia in the pursuit of achieving normoglycemia.

In this study, postoperative glucose levels and their variability were both significantly higher among those with an A1C ≥7% ([Table 2](#T2){ref-type="table"}), despite efforts to keep blood glucose levels to \<180 mg/dL, per institutional guidelines. In the subgroup analysis comparing patients who developed postoperative complications to those who did not, A1C levels and glycemic variability were significantly higher among those who developed complications, whereas mean glucose on the first postoperative day did not differ significantly ([Table 3](#T3){ref-type="table"}). This could suggest that factors other than hyperglycemia may be contributing to postoperative complications.

Knapik et al. ([@B9]), in a retrospective study, looked at the prevalence of elevated A1C and its association with postoperative complications such as stroke, renal failure, wound infection, and perioperative myocardial infarction in 2,665 patients undergoing coronary artery surgery. Of the 782 who had diabetes (29%), 283 (38%) had an A1C \>7%. The only association they found with elevated A1C was a higher incidence of perioperative myocardial infarction ([@B9]). Halkos et al. ([@B8]) showed that A1C \>8.6% was associated with a fourfold increase in mortality in patients undergoing coronary artery bypass surgery. Acott et al. ([@B11]) in a retrospective review of nearly 39,000 patients undergoing major surgery, observed that of the 2,960 patients with diabetes, 780 (26%) developed one or more complications. They showed that patients with diabetes were at increased risk for complications and death after surgery compared to those who did not have diabetes, but the risk did not correlate with A1C levels.

As the prevalence of diabetes increases in the population, it seems likely that there will be a corresponding increase in the number of people with diabetes who need scheduled surgery ([@B16]). The important socioeconomic question, then, is whether A1C levels should be measured preoperatively in all patients with diabetes. A1C is a measure of glycemic control, and the cause of poor glycemic control could be multifactorial, encompassing both noncompliance to treatment and poor response to treatment. An elevated A1C result, unlike a single preoperative glucose value, could predict difficulty in achieving postoperative glycemic control and the development of complications. Although the evidence showing an association between elevated A1C and postoperative complications is inconsistent ([@B15],[@B17],[@B18]), the authors of a recent editorial ([@B19]) argue that a preoperative A1C screening for all patients with diabetes is justified by the fact that a relatively inexpensive test can identify candidates for increased surveillance to prevent a potentially serious complication.

This prospective study, in which a small sample of patients with diabetes were observed for adverse outcomes in the immediate postoperative period, has resulted in more questions than answers. Among these questions are:Is postoperative morbidity the result of hyperglycemia or of poor long-term glycemic control or both? The fact that the mean glucose value on the first postoperative day was comparable between those who developed complications and those who did not ([Table 3](#T3){ref-type="table"}) suggests that hyperglycemia may not be the only relevant factor for wound complications. In a patient with poor long-term glycemic control, the development of postoperative complications could either be a consequence of glycosylation of tissue proteins and impaired neutrophil activity or a direct consequence of elevated A1C. Either way, however, an elevated A1C could be an easily measured marker.Should elective surgery in a patient with an elevated A1C be rescheduled? If so, what would be an acceptable A1C level for surgery? In this study, the median A1C among patients who developed complications was 7.9%, compared to 6.5% among those who did not have complications.

In summary, patients with A1C ≥7% have a greater incidence of surgical wound complications and also wider postoperative glycemic variability. Although a standard protocol was used for glycemic control in all of the patients in this study, glycemic control was more difficult to maintain in those with higher A1C values. Given the current trend of implementing a perioperative "surgical home" and reducing postoperative hospital days and readmissions ([@B20]), it seems prudent to optimize glycemic control before scheduling patients for elective surgery. A1C could be a valuable indicator in such efforts.
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